Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Brodalumab (Siliq) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have not responded or have lost response to other systemic therapies. It is highly effective in achieving Psoriasis Area and Severity Index (PASI) 90 and PASI 100 responses during short-term treatment.
• Information on brodalumab's efficacy, safety, and comparative analysis comes from a total of 18 systematic reviews/meta-analyses.
• Compared with other biologics such as infliximab, ixekizumab, secukinumab, guselkumab, and risankizumab, brodalumab has shown comparable or superior effectiveness in achieving high levels of skin clearance during the short-term treatment phase.
• Studies on the safety profile indicate that the rates of serious adverse events for brodalumab do not significantly differ from those of placebos. However, caution should be exercised due to low-to-moderate quality evidence regarding these interventions' safety profiles.
• Analysis of population considerations reveals robust evidence supporting brodalumab's efficacy among an average patient population aged around 45 years with a mean PASI score of 20; however, this may not reflect broader patient demographics seen in daily clinical practice. Subgroup analyses suggest potential differences based on prior biological therapy exposure, indicating the need for personalized treatment strategies based on individual patient history.
• Targeted subgroup analyses focused on nail psoriasis and psoriatic arthritis show promise, suggesting potential utility beyond plaque psoriasis, which could address significant impairment areas impacting patients' quality of life.
• Evaluation of long-term outcomes indicates that newer biologics like Siliq maintain high efficacy over time, making it a competitive option for sustained disease management given its durability, including maintenance at PASI 75/90/100 responses after one year.
• Synthesized data, despite the lack of direct head-to-head trials for all relevant comparators, positions brodalumab among the top choices for achieving higher PASI response rates, especially considering short-term efficacy data. This emphasizes its role in treatment strategies, particularly for patients prioritizing rapid and significant skin clearance.